Clinical Trial Update: Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H) [Phase 2]

View source ↗

Summary

Phase 2 MATCH subprotocol study evaluating copanlisib as a targeted treatment for cancers with PTEN expression. The trial is currently active but not recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Multiple Myeloma
• Solid Tumor

Drugs mentioned

• Copanlisib (copanlisib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-04-16